Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research

升级匹兹堡大学疫苗研究中心区域生物防护实验室的行政补充

• 批准号: 10631339
• 负责人: William Paul Duprex
• 金额: $ 332.97万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-22 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10631339
• 关键词: Acceleration; Achievement; Address; Administrative Supplement; Aging; Animals; Applications Grants; Award; Biological; Biology; COVID-19 pandemic; Capital; Categories; Cells; Cities; Communities; Confocal Microscopy; Contractor; Diagnostic; Discipline; Ecosystem; Elements; Emerging Communicable Diseases; Ensure; Equipment; Evolution; Ferrets; Four-dimensional; Funding; Goals; Health; Human; Hydrogen Peroxide; Immunologics; In Vitro; Infection; Infectious Agent; Infectious Diseases Research; Infrastructure; Institution; Intervention; Knowledge; Laboratories; Leadership; Molecular; National Institute of Allergy and Infectious Disease; Oryctolagus cuniculus; PET/CT scan; Paper; Parents; Pathogenesis; Pathologic; Pennsylvania; Persons; Public Health; Publications; Recording of previous events; Research; Research Infrastructure; Research Personnel; Resources; Rodent; Structural Biologist; Therapeutic antibodies; Time; Tissues; Toxin; Training; Translating; Translational Research; United States National Institutes of Health; Universities; Vaccine Research; Vaccines; Viral; Virus; Vision; Work; biodefense; bioimaging; cohort; cost effective; experience; faculty research; flexibility; in vivo imaging system; medical schools; multimodality; nanobodies; novel; operation; pandemic disease; pandemic preparedness; parent project; pathogen; preclinical development; priority pathogen; programs; recruit; response; small molecule inhibitor; success; vapor

ABSTRACT: The Center for Vaccine Research (CVR) investigators conduct research on BSL-3 Category A, B, and C priority pathogens that have an impact on the health of people around the world. This is facilitated by the integral NIAID supported Regional Biocontainment Laboratory (RBL) which provides biosafety level (BSL)-2 and animal (A)BSL-3 capabilities. CVR is the hub for infection biology at the University of Pittsburgh bringing together virologists, bacteriologists, biochemists, structural biologists and clinicians from a variety of disciplines who have a common goal of investigating the evolution and pathogenesis of emerging infectious diseases and biodefense pathogens. The center enables the acceleration of pre-clinical development of novel interventions such as vaccines, therapeutic antibodies and nanobodies, small molecule inhibitors and diagnostics for viruses and other infectious agents. In 2021 CVR received a $3.3 million award to support fixed and non-fixed equipment upgrades within the RBL (G20AI167405). In this supplement to the parent, we focus on addressing scientific deficits and concentrate on the lack of flexible ABSL-3 space, small animal bioimaging capabilities and revitalizing core, shared equipment. Multimodal bioimaging capabilities are integral elements in understanding how pathogens infect cells, tissues and animals in four-dimensions. In this supplement we will expand our bioimaging capabilities to small and medium sized animals to augment our active large animal programs. These upgrades will be integrated into the current G20 parent project making it very cost effective in terms of recommissioning the facility. This ensure the supplement is fully within the scope of the parental award. This will ensure the University of Pittsburgh RBL remains fit-for-purpose and emerging infectious disease response-ready for another fifteen years. The facility is considered essential research infrastructure by the University of Pittsburgh, for the region, the state and nation. CVR staff have made major contributions to the ongoing COVID-19 pandemic by leveraging their significant experience working on pathogens with pandemic potential in biocontainment. Maintaining well trained, response ready cohorts of infection biologists across nation is vitally important as pathogens will continue to emerge. This makes pandemic preparedness an essential element of the national research portfolio.

抽象的： 疫苗研究中心（CVR）研究人员对BSL-3类别A，B和C优先级进行研究 病原体会影响世界各地人民的健康。这是由整体NIAID促进的 提供生物安全水平（BSL）-2和动物的支持区域生物疗养实验室（RBL） （a）BSL-3功能。 CVR是匹兹堡大学感染生物学的枢纽 病毒学家，细菌学家，生物化学家，结构生物学家和临床医生来自各种学科 研究新兴感染性疾病和生物性疾病的进化和发病机理的共同目标 病原体。该中心可以加速新的干预措施（例如 疫苗，治疗性抗体和纳米体，小分子抑制剂和病毒和其他的诊断 感染者。 2021年，CVR获得了330万美元的奖励，以支持固定和非固定设备升级 在RBL内（G20AI167405）。在对父母的补充中，我们专注于解决科学缺陷和 集中精力缺乏柔性ABSL-3空间，小型动物生物成像能力和振兴核心， 共享设备。多模式的生物成像能力是理解病原体的组成部分 在四维中感染细胞，组织和动物。在这种补充中，我们将扩大我们的生物成像 中小型动物的能力增加了我们活跃的大型动物计划。这些升级 将集成到当前的G20父级项目中，使其在建议方面非常有效 设施。这确保补充剂完全属于父母奖的范围。这将确保 匹兹堡大学RBL仍然适合用途和新兴的感染性疾病，以应对另一种 十五年。该设施被匹兹堡大学视为必不可少的研究基础设施 地区，国家和国家。 CVR工作人员已为正在进行的Covid-19-19的大流行做出了重大贡献。 利用他们在生物培养中具有大流行潜力的病原体上工作的丰富经验。 在国家维持经过良好训练，备受反应的现成感染生物学家，至关重要，因为 病原体将继续出现。这使大流行准备成为民族的重要因素 研究组合。